AlbaajF., HutchisonA.J.Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients.Expert Opin Pharmacother2005; 6: 319–28.
2.
FinnW.F., JoyM.S.A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.Curr Med Res Opin2005; 21: 657–64.
3.
AlbaajF., HutchisonA.J.Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients.Int J Clin Pract2005; 59: 1091–6.
4.
ShigematsuT; Lanthanum Carbonate Research Group. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis.Ther Apher Dial2008; 12: 55–61.
5.
CoburnJ.W.Mineral metabolism and renal bone disease: effects of CAPD versus hemodialysis.Kidney Int Suppl1993; 40: S92–100.
6.
JoffeP., PodenphantJ., HeafJ.G.Bone histology in CAPD patients: a comparison with hemodialysis and conservatively treated chronic uremics.Adv Perit Dial1989; 5: 171–6.
